Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype

被引:52
作者
Mikus, G [1 ]
Trausch, B [1 ]
Rodewald, C [1 ]
Hofmann, U [1 ]
Richter, K [1 ]
Gramatte, T [1 ]
Eichelbaum, M [1 ]
机构
[1] TECH UNIV DRESDEN,INST KLIN PHARMAKOL,D-8027 DRESDEN,GERMANY
关键词
D O I
10.1016/S0009-9236(97)90196-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Codeine is widely used as an analgesic and antitussive drug. The analgesic effect of codeine is mediated by its metabolite morphine, which is formed by the polymorphically expressed enzyme CYP2D6; therefore poor metabolizers have no analgesia after administration of codeine. Like other opiates, codeine causes a delay of gastric emptying and spastic constipation. It is not yet known whether the effect on gastrointestinal motility is mediated by codeine or its metabolite morphine. Methods: To test the hypothesis that the metabolite morphine is responsible for the effects of codeine on gastrointestinal motility, a randomized, double-blind, two-way crossover study was performed. The orocecal transit time was studied in five extensive and five poor metabolizers of sparteine with the sulfasalazine-sulfapyridine method, assuming that no effects are observed in poor metabolizers because negligible amounts of morphine are formed. Results: No differences of orocecal transit times were observed between extensive metabolizers and poor metabolizers after oral placebo administration. However, after oral codeine administration orocecal transit time was significantly prolonged in extensive metabolizer but not poor metabolizer subjects. ALL pharmacokinetic parameters of codeine showed no differences between extensive metabolizers and poor metabolizers. The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mu mol). Conclusions: Because the orocecal transit time prolongation after codeine administration was observed only in extensive metabolizers, the effect of codeine on gastrointestinal motility, like the analgesia, is mediated by its metabolite morphine.
引用
收藏
页码:459 / 466
页数:8
相关论文
共 33 条
[1]   QUANTITATIVE, NONINVASIVE ASSESSMENT OF ANTIDIARRHEAL ACTIONS OF CODEINE USING AN EXPERIMENTAL-MODEL OF DIARRHEA IN MAN [J].
BARROW, L ;
STEED, KP ;
SPILLER, RC ;
MASKELL, NA ;
BROWN, JK ;
WATTS, PJ ;
MELIA, CD ;
DAVIES, MC ;
WILSON, CG .
DIGESTIVE DISEASES AND SCIENCES, 1993, 38 (06) :996-1003
[2]  
CHEN ZR, 1988, LANCET, V2, P914
[3]  
CLEARY J, 1992, CLIN EXP PHARM PHY S, V21, P66
[4]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201
[5]   BIOACTIVATION OF THE NARCOTIC DRUG CODEINE IN HUMAN-LIVER IS MEDIATED BY THE POLYMORPHIC MONOOXYGENASE CATALYZING DEBRISOQUINE 4-HYDROXYLATION (CYTOCHROME-P-450 DBL/BUFI) [J].
DAYER, P ;
DESMEULES, J ;
LEEMANN, T ;
STRIBERNI, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 152 (01) :411-416
[6]   IMPACT OF ENVIRONMENTAL AND GENETIC-FACTORS ON CODEINE ANALGESIA [J].
DESMEULES, J ;
GASCON, MP ;
DAYER, P ;
MAGISTRIS, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (01) :23-26
[7]   POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE - RELATED PHARMACOGENETIC ENTITIES [J].
EICHELBAUM, M ;
BERTILSSON, L ;
SAWE, J ;
ZEKORN, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (02) :184-186
[8]  
EVERT B, 1994, N-S ARCH PHARMACOL, V350, P434
[9]   CLONING AND SEQUENCING OF A NEW NONFUNCTIONAL CYP2D6 ALLELE - DELETION OF T-1795 IN EXON-3 GENERATES A PREMATURE STOP CODON [J].
EVERT, B ;
GRIESE, EU ;
EICHELBAUM, M .
PHARMACOGENETICS, 1994, 4 (05) :271-274
[10]   DIHYDROCODEINE - A NEW OPIOID SUBSTRATE FOR THE POLYMORPHIC CYP2D6 IN HUMANS [J].
FROMM, MF ;
HOFMANN, U ;
GRIESE, EU ;
MIKUS, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) :374-382